Amgen (AMGN) call put ratio 1 call to 1.26 puts after reporting Repatha data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Amgen (AMGN) FOURIER Results 'Good Enough' - Cowen
March 17, 2017 11:23 AM EDTCowen analyst Eric Schmidt weighed in on Amgen (NASDAQ: AMGN) after the highly anticipated FOURIER CV outcomes data details were presented at ACC. The firm maintained an Outperform rating and price target of $209 on AMGN. He said the results were "good enough" to gradually transform... More
While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman Sachs
March 17, 2017 11:05 AM EDTGoldman Sachs analyst Terence Flynn weighed in on Amgen (NASDAQ: AMGN) after full data from Repatha (PCSK9) Ph3 cardiovascular outcomes trial, FOURIER, was presented.
Flynn commented, "In our view the primary endpoint effect is likely below investor expectations (hence why AMGN... More



